TITLE

GIDEON: Oncologists give lower doses, shorter duration of sorafenib for hepatocellular carcinoma

AUTHOR(S)
Harris, Jason
PUB. DATE
February 2011
SOURCE
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p19
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the results of a study which found that oncologists in the U.S. prescribe shorter duration and lower doses of sorafenib for hepatocellular carcinoma.
ACCESSION #
62393624

 

Related Articles

  • Radiofrequency ablation of malignant hepatic neoplasms. Chan, Raymond P.; Asch, Murray; Kachura, John; Chia-Sing Ho; Greig, Paul; Langer, Bernard; Sherman, Morris; Wong, Florence; Feld, Ronald; Gallinger, Steven // Canadian Association of Radiologists Journal;Dec2002, Vol. 53 Issue 5, p272 

    Objective: To assess the safety and efficacy of radiofrequency ablation (RFA) in the treatment of malignant neoplasms of the liver. Methods: Sixty-seven patients received RFA for primary or secondary hepatic malignancies. Patients were followed prospectively with computed tomography (CT)...

  • Filtering out cancer's side-effects.  // New Scientist;11/14/92, Vol. 136 Issue 1847, p20 

    Describes a filtration system developed by surgeons in the United States that reduces the toxic side-effects of the drug adriamycin that is commonly used to treat liver cancer. Results of studies in animals; What the filtration system consists of; Possible drawback of the system.

  • FOLFOX4 outperformed doxorubicin in advanced hepatocellular carcinoma.  // Hem/Onc Today;3/10/2011, Vol. 12 Issue 5, p24 

    The article discusses a research study, led by Doctor Sumitra Thongprasert, which found that the chemotherapy regimen FOLFOX4 yielded higher overall survival (OS) rate compared to doxorubicin in advanced hepatocellular carcinoma.

  • Irradiated glass effective cancer theraphy.  // R&D Magazine;Sep95, Vol. 37 Issue 10, p108 

    Reports on the successful testing of irradiated glass beads for the use of treating liver cancer. Information on the treating while reference to Delbert Day of the University of Missouri-Rolla (UMR); Contact information available for UMR.

  • HCC treatment underutilized in United States.  // Hem/Onc Today;11/10/2013, Vol. 14 Issue 21, p35 

    The article discusses a research paper on the status of hepatocellular carcinoma treatment in the U.S., which references a study by D. Tan et al., published in a 2013 issue of "Alimentary Pharmacology & Therapeutics."

  • Practical Considerations in the Treatment of Hepatocellular Carcinoma. Colleoni, M.; Audisio, R.A.; Braud, F.D.; Fazio, N.; Martinelli, G.; Goldhirsch, A. // Drugs;Mar1998, Vol. 55 Issue 3, p367 

    Hepatocellular carcinoma (HCC) represents one of the most common neoplasms worldwide. To date, curative treatment options include liver transplantation or resection. Unfortunately, most patients are detected with nonresectable or -transplantable HCC due to disease extension or comorbid factors,...

  • Hepatocellular carcinoma patients may benefit from left hemi-hepatectomy with caudate lobectomy. Hongyu Li; Bo Li; Yonggang WeI // Pakistan Journal of Medical Sciences;Jan-Mar2013, Vol. 29 Issue 1, p249 

    A letter to the editor is presented on topic related to use of left hemi-hepatectomy with caudate lobectomy as the first-line treatment for the hepatocellular carcinoma (HCC) patients having left portal vein tumor thrombus.

  • ABLATION OF HEPATOCELLULAR CARCINOMA. Takayama, Tadatoshi // Japanese Journal of Clinical Oncology;Jul2001, Vol. 31 Issue 7, p297 

    Editorial. Comments on the use of ablation therapy in treating patients with hepatocellular carcinoma. Evaluation of therapeutic effect; Replacement of percutaneous ethanol injection; Cost of ablation.

  • Gemcitabine/oxaliplatin treatment effective in patients with advanced HCC.  // Hem/Onc Today;11/10/2012, Vol. 13 Issue 21, p23 

    The article reports on the results of a retrospective multicenter study concerning the response of patients with hepatocellular carcinoma to therapy with gemcitabine and oxaliplatin.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics